• Fri news: Gilead withdraws bladder cancer drug. Amgen and Intercept PDUFA date pushback. CVS replaces CEO. Supernus depression trial. AbbVie Parkinson’s approval. See more on our front page

Gilead gets beat by Merck.









so much for the acquisitions for investments that won't possibly generate any value until after 2025....we got a lot of pretty slides and story-telling about oncology is the future, while Merck and other players are focused on making a difference now